Informational only. Nothing on this page is an investment offer, a live raise, or medical advice.

The candidate

NWPT-SM32300 is NWPharmaTech’s investigational 300 mg CBD micellar-emulsion softgel. The CHR-P programme is organised around a planned Phase 2B study of this candidate.

Conceptual illustration of micelle-like droplets suspended in liquid.
Conceptual illustration of the investigational micellar-emulsion motif, not to scale — not clinical evidence of efficacy.

Effectiveness in this population has not been established. This is an investigational description — not an approved CHR-P medicine. Programme lead: Professor Scott Woods (individual scientific capacity); see Team.

Current public scientific step — planned Phase 2B

The planned Phase 2B study is designed to evaluate dose response, symptoms, safety and tolerability, and to inform the next stage of development. The proposed design includes approximately 328 participants receiving placebo or one of three daily doses over 12 weeks, with follow-up at week 16.

Prevention is a separate question. Delay or prevention of transition to psychosis remains a longer-term research aim. It must be separately powered if claimed as a primary objective. Positive work on symptoms would not, by itself, prove population-level prevention.

What remains open

  • CHR-P efficacy for NWPT-SM32300 — not established
  • Prevention of psychosis — mission-level research question, not a demonstrated result
  • Numerical exposure or safety figures — not published here until formal study reports are available
  • Primary outcome details and operational finalisation — ongoing

Sponsor governance

NWPharmaTech remains the pharmaceutical sponsor for clinical development, safety, CMC and regulatory strategy. Investigators, ethics committees and regulators keep their independent roles. Community or financing participants do not vote on protocol, dose, endpoints, safety or submissions.

Financing note (planning only)

Any financing discussion remains planning-only and inactive on this public site. This page is not an offer and does not accept investments.

How to read related evidence

Field CBD studies (including adjunctive work in schizophrenia with other products) are hypothesis-generating only. They are not NWPT-SM32300 data and not CHR-P prevention evidence for this programme. See the evidence library for labelled sources.

Programme brief · Phase 2B overview · Science · Why early intervention matters · Governance